Novel lipoplex nanoparticle to be used in 1st human trial treating advanced solid cancerAugust 25, 2005Washington D.C. - The first clinical trial of a biologic nanoparticle designed to give back to cancer patients the tumor-busting gene they have lost is expected to start in September at Georgetown University Medical Center. The phase I clinical study will enroll 20 patients with advanced solid cancers (including most common tumor types), and is the culmination of more than a decade of work by a team of researchers led by Professor Esther H. Chang, Ph.D. at the Lombardi Comprehensive Cancer Center. Their research has led to development of a tiny structure - measuring a millionth of an inch across - that resembles a virus particle that can penetrate deeply into the tumor and move efficiently into cells. The device is a "liposome" - a microscopic globule made of lipids - that is spiked on the outside with antibody molecules that will seek out, bind to, and then enter cancer cells including metastases wherever they hide in the body. These molecules bind to the receptor for transferrin that is present in high numbers on cancer cells. Once inside, the nanoparticle, which the researchers call a "immunolipoplex," will deliver its payload - the p53 gene whose protein helps to signal cells to self-destruct when they have the kind of genetic damage characterized by cancer and by cancer therapies. More than half of all cancer patients have cancer cells that have lost normal functioning of the p53 gene, so-called "guardian of the genome," and the Georgetown researchers believe that restoring the gene will improve the tumor-killing ability of traditional treatments. "We are excited about the promise this nanoparticle has shown in animal tumor models, and are anxious to offer it to patients," said Chang, Professor in the Department of Oncology and Co-director of the Molecular Targets & Developmental Therapeutics Program at Georgetown. The federal Food and Drug Administration granted approval for the trial to begin in late July. The work is being sponsored by grants from the National Institutes of Health and private foundations. Additional support comes from SynerGene Therapeutics, a biotech research firm with which Chang collaborates. John Marshall, M.D., Director of Developmental Therapeutics and GI Oncology at Georgetown, will serve as the trial's principal investigator. The researchers believe that immunolipoplex represents an advance over the viral "vectors" that have been used to deliver gene therapy, because these liposomes do not produce the kinds of immunologic response seen when disabled viruses are used to carry the payload. They also say that the nanoparticle is of a small uniform size and consistency, and has been proven to work in animals bearing tumor. In preclinical research, Chang and long-term research colleague Kathleen Pirollo, Ph.D. have found that these nanoparticles substantially improve the tumor-fighting power of both chemotherapy and radiation therapy. These agents work synergistically with traditional therapies because the newly restored p53 protein helps push cancer cells that are now damaged to self-destruct. "We believe this approach will make it difficult for the cancer cells to become resistant to therapy," Chang said. "As a result, cancers treated with these liposomal formulations should be less likely to recur after therapy is complete." For example, use of these p53-loaded liposomes in combination with radiation therapy eliminated prostate and head and neck tumors in mice, which then survived cancer-free for more than 200 days - until they all died of old age. Similar promising results were seen when the nanoparticles were combined with chemotherapy to treat animal models of melanoma and aggressive breast cancer. Among the solid tumors approved for testing in the clinical trial are head and neck, prostate, pancreatic, breast, bladder, colon, cervical, brain, melanoma, liver and lung cancers. Georgetown University Medical Center |
|||||||||||||||||||||
| Related Nanoparticle Current Events and Nanoparticle News Articles Multifunctional nanoparticle enables new type of biological imaging Spotting a single cancerous cell that has broken free from a tumor and is traveling through the bloodstream to colonize a new organ might seem like finding a needle in a haystack. Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells Using chemical "nanoblasts" that punch tiny holes in the protective membranes of cells, researchers have demonstrated a new technique for getting therapeutic small molecules, proteins and DNA directly into living cells. Protein from poplar trees can be used to greatly increase computer capacity Scientists from the Hebrew University of Jerusalem have succeeded in showing how it is possible to greatly expand the memory capacity of future computers through the use of memory units based on silica nanoparticles combined with protein molecules obtained from the poplar tree. Researchers use nanoparticles as destructive beacons to zap tumors A group of researchers from Wake Forest University Baptist Medical Center (WFUBMC) is developing a way to treat cancer by using lasers to light up tiny nanoparticles and destroy tumors with the ensuing heat. University of Toronto chemists make breakthrough in nanoscience research A team of scientists led by Eugenia Kumacheva of the Department of Chemistry at the University of Toronto has discovered a way to predict the organization of nanoparticles in larger forms by treating them much the same as ensembles of molecules formed from standard chemical reactions. Researchers apply computing power to crack egg shell problem Researchers at the University of Warwick and the University of Sheffield have applied computing power to crack a problem in egg shell formation. The work may also give a partial answer to the age old question "what came first the chicken or the egg?" Researchers develop drug delivery system using nanoparticles triggered by electromagnetic field A new system for the controlled delivery of pharmaceutical drugs has been developed by a team of University of Rhode Island chemical engineers using nanoparticles embedded in a liposome that can be triggered by non-invasive electromagnetic fields. For platinum catalysts, smaller may be better When it comes to metal catalysts, the platinum standard is, well, platinum! However, at about $2,000 an ounce, platinum is more expensive than gold. The high cost of the raw material presents major challenges for the future wide scale use of platinum in fuel cells. Research at the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) suggests that one possible way to meet these challenges is to think small - really small. Evidence that nanoparticles in sunscreens could be toxic if accidentally eaten Scientists are reporting that particle size affects the toxicity of zinc oxide, a material widely used in sunscreens. Particles smaller than 100 nanometers are slightly more toxic to colon cells than conventional zinc oxide. 'Instant acid' method offers new insight into nanoparticle dispersal in the environment and the body Using a chemical trick that allows them to change the acidity of a solution almost instantly, a team at the National Institute of Standards and Technology (NIST) has demonstrated a simple and effective technique for quantifying how the stability of nanoparticle solutions change when the acidity of their environment suddenly changes. More Nanoparticle Current Events and Nanoparticle News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||